Brief: Glenmark Pharma Sept-Quarter Consol Net Profit At 6.1 Billion Rupees
14/11/2025 12:24
Nov 14 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS: SEPT-QUARTER CONSOL NET PROFIT 6.1 BILLION RUPEES SEPT-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 60.47 BILLION RUPEES Source text: ID:nBSEQHh1F Further company coverage: GLEN.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter